A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Trial Profile

A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Lenvatinib (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms REFLECT
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 31 Oct 2017 According to an Eisai Co Ltd media release, the China Food and Drug Administration (CFDA) has accepted for review a New Drug Application (NDA) submitted for lenvatinib mesylate in hepatocellular carcinoma.NDA was based on the result of this study.
    • 28 Oct 2017 This study has been completed in Spain.
    • 24 Oct 2017 Results assessing efficacy and safety outcomes for patients with baseline HBV presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top